CA3239301A1 - Methods of treating idiopathic pulmonary fibrosis with deupirfenidone - Google Patents

Methods of treating idiopathic pulmonary fibrosis with deupirfenidone Download PDF

Info

Publication number
CA3239301A1
CA3239301A1 CA3239301A CA3239301A CA3239301A1 CA 3239301 A1 CA3239301 A1 CA 3239301A1 CA 3239301 A CA3239301 A CA 3239301A CA 3239301 A CA3239301 A CA 3239301A CA 3239301 A1 CA3239301 A1 CA 3239301A1
Authority
CA
Canada
Prior art keywords
subject
lyt
treatment
pirfenidone
tid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3239301A
Other languages
English (en)
French (fr)
Inventor
Michael C. Chen
Eric Elenko
Heather A. PADEN
Christopher C. KORTH
Paul Andrew FORD
Julie S. KROP
Camilla S. GRAHAM
Liza C. MICIONI
Simon John HATCH
Varun Garg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puretech LYT 100 Inc
Original Assignee
Puretech LYT 100 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech LYT 100 Inc filed Critical Puretech LYT 100 Inc
Publication of CA3239301A1 publication Critical patent/CA3239301A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3239301A 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone Pending CA3239301A1 (en)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US202263296826P 2022-01-05 2022-01-05
US202263296818P 2022-01-05 2022-01-05
US202263296843P 2022-01-05 2022-01-05
US63/296,843 2022-01-05
US63/296,826 2022-01-05
US63/296,818 2022-01-05
US202263326132P 2022-03-31 2022-03-31
US202263326129P 2022-03-31 2022-03-31
US63/326,132 2022-03-31
US63/326,129 2022-03-31
US202263341269P 2022-05-12 2022-05-12
US202263341279P 2022-05-12 2022-05-12
US202263341281P 2022-05-12 2022-05-12
US63/341,281 2022-05-12
US63/341,269 2022-05-12
US63/341,279 2022-05-12
US202263341828P 2022-05-13 2022-05-13
US63/341,828 2022-05-13
US202263352107P 2022-06-14 2022-06-14
US63/352,107 2022-06-14
US202263356653P 2022-06-29 2022-06-29
US63/356,653 2022-06-29
US202263374362P 2022-09-01 2022-09-01
US63/374,362 2022-09-01
US202263403481P 2022-09-02 2022-09-02
US63/403,481 2022-09-02
US202263431530P 2022-12-09 2022-12-09
US63/431,530 2022-12-09
US202263432208P 2022-12-13 2022-12-13
US63/432,208 2022-12-13
PCT/US2023/060185 WO2023133476A1 (en) 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Publications (1)

Publication Number Publication Date
CA3239301A1 true CA3239301A1 (en) 2023-07-13

Family

ID=87074293

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3239301A Pending CA3239301A1 (en) 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Country Status (9)

Country Link
US (1) US20240358690A1 (https=)
EP (1) EP4460305A4 (https=)
JP (1) JP2025502023A (https=)
KR (1) KR20240131352A (https=)
AU (1) AU2023205787A1 (https=)
CA (1) CA3239301A1 (https=)
IL (1) IL314022A (https=)
MX (1) MX2024008476A (https=)
WO (1) WO2023133476A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511066A (ja) * 2022-03-31 2025-04-15 ピュアテック・エル・ワイ・ティ・１００・インコーポレイテッド デューピルフェニドンにより間質性肺疾患ならびに他の線維化介在性肺疾患及び障害を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
EP4603148A3 (en) * 2018-09-14 2025-10-29 Puretech Lyt 100, Inc. Deuterium-enriched pirfenidone and methods of use thereof
CA3171622A1 (en) * 2020-03-13 2021-09-16 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone

Also Published As

Publication number Publication date
JP2025502023A (ja) 2025-01-24
WO2023133476A1 (en) 2023-07-13
US20240358690A1 (en) 2024-10-31
EP4460305A1 (en) 2024-11-13
MX2024008476A (es) 2024-07-12
EP4460305A4 (en) 2025-12-31
IL314022A (en) 2024-08-01
AU2023205787A1 (en) 2024-06-13
KR20240131352A (ko) 2024-08-30

Similar Documents

Publication Publication Date Title
US12251381B2 (en) Aripiprazole dosing strategy
TW202110451A (zh) 使用布魯頓酪胺酸激酶抑制劑治療休格倫氏症候群之方法
US20230255946A1 (en) Methods of treating diseases and disorders with deupirfenidone
AU2025203171A1 (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
Boettcher et al. Vericiguat in combination with short‐acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study
US20240358690A1 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
CN103083325A (zh) 治疗女性性功能障碍的包含他达拉非的药物剂型
US20250114341A1 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
US20250249001A1 (en) Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators
US20250114340A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
HK40114519A (zh) 用氘吡非尼酮治疗特发性肺纤维化的方法
CN118510510A (zh) 用氘吡非尼酮治疗特发性肺纤维化的方法
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
Groseanu et al. FRI0256 Significance of cognitive impairment in systemic sclerosis
US20240122928A1 (en) Methods For Treating Agitation In Subjects With Mild Cognitive Impairment Or Major Neurocognition Disorder
JP7806102B2 (ja) 慢性腎疾患に関連する貧血を有する対象における疲労軽減のためのダプロデュスタット
Alas-Pineda et al. Cardiac Safety of Intranasal Chlorpheniramine: An Exposure-Based Risk Assessment
Zhang et al. The Real‐World Analysis of Adverse Events With Two Types of Single‐Inhaler Triple Therapy: A VigiAccess Database Study
US20230381190A1 (en) Methods and Treatment for Complex Lymphatic Malformations
WO2024173873A2 (en) Compounds, compositions, and methods for treating, ameliorating, and/or preventing pain
KR20260056206A (ko) 국소 분절 사구체경화증을 치료하기 위한 trpc6의 억제제
DEVELOPM Drug DeveloPment
TW202535397A (zh) 給藥方案
EP4499094A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251229

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251229